Evidence map›Paper›PMID 36147922›Full record

ArticleFrontiers in oncology2022

Myoferlin disturbs redox equilibrium to accelerate gastric cancer migration.

Hailong Shi, Yuanyuan Cheng, Qimei Shi, Wenzhi Liu, Xue Yang, Shuang Wang, Lin Wei, Xiangming Chen, Hao Fang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hailong ShiDepartment of Chemotherapy, Tai'an City Central Hospital, Tai'an, China.
Yuanyuan ChengDepartment of Chemotherapy, Tai'an City Central Hospital, Tai'an, China.
Qimei ShiDepartment of Chemotherapy, Tai'an City Central Hospital, Tai'an, China.
Wenzhi LiuDepartment of Chemotherapy, Tai'an City Central Hospital, Tai'an, China.
Xue YangDepartment of Chemotherapy, Tai'an City Central Hospital, Tai'an, China.
Shuang WangDepartment of Chemotherapy, Tai'an City Central Hospital, Tai'an, China.
Lin WeiDepartment of Chemotherapy, Tai'an City Central Hospital, Tai'an, China.
Xiangming ChenDepartment of Chemotherapy, Tai'an City Central Hospital, Tai'an, China.
Hao FangDepartment of Gastroenterology, Tai'an City Central Hospital, Tai'an, China.
Taian City Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: In contrast to normal cells, in which reactive oxygen species (ROS) are maintained in redox equilibrium, cancer cells are characterized by ectopic ROS accumulation. Myoferlin, a newly identified oncogene, has been associated with tumor metastasis, intracellular ROS production, and energy metabolism. The mechanism by which myoferlin regulates gastric cancer cell migration and ROS accumulation has not been determined. Methods: Myoferlin expression, intracellular ROS levels, the ratios of reduced to oxidized glutathione (GSH/GSSG) and nicotinamide adenine dinucleotide phosphate (NADPH/NADP+) and migratory ability were measured in gastric cancer cells Results: Myoferlin was found to be more highly expressed in tumor than in normal tissues of gastric cancer patients, with higher expression of Myoferlin associated with shorter survival time. Myoferlin was associated with significantly higher intracellular ROS levels and enhanced migration of gastric cancer cells. N-acetyl-L-cysteine (NAC), a potent inhibitor of ROS, inhibited Myoferlin Conclusions: Myoferlin is a candidate prognostic biomarker for gastric cancer and plays an essential role in regulating redox equilibrium and gastric cancer cell migration. Myoferlin may also be a new target for treatment of patients with gastric cancer.

Indexed as

gastric cancerGSHmetastasismyoferlinROS

Identifiers

PMID36147922
PMCPMC9486956
OpenAlexW4294740413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.